SuperworthSight Sciences EPS SGHT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.56
- Latest quarter, Q2 FY26
- −$0.08
- Fiscal year 2025
- −$0.75
Sight Sciences' earnings per share was −$0.56 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.75 | n/a |
| FY2024 | −$1.03 | n/a |
| FY2023 | −$1.14 | n/a |
| FY2022 | −$1.80 | n/a |
| FY2021 | −$3.89 | n/a |
| FY2020 | −$3.71 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.08 | n/a | −$0.56 | |
| Q1 FY26 | −$0.24 | n/a | −$0.71 | |
| Q4 FY25 | −$0.08 | n/a | −$0.75 | |
| Q3 FY25 | −$0.16 | n/a | −$0.90 | |
| Q2 FY25 | −$0.23 | n/a | −$0.96 | |
| Q1 FY25 | −$0.28 | n/a | −$0.98 | |
| Q4 FY24 | −$0.23 | n/a | −$1.03 | |
| Q3 FY24 | −$0.22 | n/a | −$1.02 | |
| Q2 FY24 | −$0.25 | n/a | −$1.07 | |
| Q1 FY24 | −$0.33 | n/a | −$1.12 | |
| Q4 FY23 | −$0.22 | n/a | −$1.14 | |
| Q3 FY23 | −$0.27 | n/a | −$1.27 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Sight Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SGHTSight Sciences | −$0.56 | |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| MDXGMimedx | $0.04 | −81% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| MOVMovado | $1.80 | +137% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| IRMDIradimed | $1.79 | +10% a year |
| STAAStaar Surgical | $0.07 | |
| PDEXPro DEX | $4.11 | +52% a year |
| BVSBioventus | $0.77 | |
| Peer median | $1.27 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Sight Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.